Abstract
Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.
Keywords: Autoimmunity, effector T cells, regulatory T cells, Teffs, Tregs, Type 1 diabetes mellitus, autoimmune disease, hyperglycemic, phenotype, antigens, autoantigens, viral infection, cytokines, insulitis, chemokines
Current Molecular Medicine
Title:Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus
Volume: 12 Issue: 10
Author(s): S.M. Cabrera, M.R. Rigby and R.G. Mirmira
Affiliation:
Keywords: Autoimmunity, effector T cells, regulatory T cells, Teffs, Tregs, Type 1 diabetes mellitus, autoimmune disease, hyperglycemic, phenotype, antigens, autoantigens, viral infection, cytokines, insulitis, chemokines
Abstract: Type 1 diabetes mellitus (T1DM) is a T cell-mediated autoimmune disease resulting in islet β cell destruction, hypoinsulinemia, and severely altered glucose homeostasis. T1DM has classically been attributed to the pathogenic actions of auto-reactive effector T cells(Teffs) on the β cell. Recent literature now suggests that a failure of a second T cell subtype, known as regulatory T cells (Tregs), plays a critical role in the development of T1DM. During immune homeostasis, Tregs counterbalance the actions of autoreactive Teff cells, thereby participating in peripheral tolerance. An imbalance in the activity between Teff and Tregs may be crucial in the breakdown of peripheral tolerance, leading to the development of T1DM. In this review, we summarize our current understanding of Treg function in health and in T1DM, and examine the effect of experimental therapies for T1DM on Treg cell number and function in both mice and humans.
Export Options
About this article
Cite this article as:
Cabrera S.M., Rigby M.R. and Mirmira R.G., Targeting Regulatory T Cells in the Treatment of Type 1 Diabetes Mellitus, Current Molecular Medicine 2012; 12 (10) . https://dx.doi.org/10.2174/156652412803833634
DOI https://dx.doi.org/10.2174/156652412803833634 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Sulfur- and Acyl Chain-Dependent Influence of 2-Methoxy-Lysophosphatidylcholine Analogues on β Pancreatic Cells
Current Topics in Medicinal Chemistry Regulation of Brain Reward by the Endocannabinoid System: A Critical Review of Behavioral Studies in Animals
Current Pharmaceutical Design Cyclic Nucleotides Signaling and Phosphodiesterase Inhibition: Defying Alzheimer’s Disease
Current Drug Targets Sirtuins as Possible Drug Targets in Type 2 Diabetes
Current Drug Targets The Effect of Oxidative Stress and Antioxidant Therapies on Pancreatic β-cell Dysfunction: Results from <i>in Vitro</i> and <i>in Vivo</i> Studies
Current Medicinal Chemistry Genetics of Gestational Diabetes Mellitus
Current Medicinal Chemistry Protective Effect of Perindopril on Tumor Progression and Angiogenesis in Animal Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry GSK-3 Inhibitors: Recent Developments and Therapeutic Potential
Current Signal Transduction Therapy Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research Metabolic Syndrome - Risk Factors for Atherosclerosis and Diabetes
Current Diabetes Reviews Prophylactic Neuroprotection
Current Drug Targets Model Checking a Synchronous Diabetes-Cancer Logical Network
Current Bioinformatics Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Gene Regulation of Aldose-, Aldehyde- and a Renal Specific Oxido Reductase (RSOR) in the Pathobiology of Diabetes Mellitus
Current Medicinal Chemistry Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets GABAergic Pharmacotherapy in the Treatment of Motor Disorders of the Central Nervous System
Current Pharmaceutical Design Cholecystokinin 1(A) Receptor Polymorphisms
Current Topics in Medicinal Chemistry Platelet Function Testing in Atherothrombotic Disease
Current Pharmaceutical Design